Faecalibacterium prausnitzii in Differentiated Thyroid Cancer Patients Treated with Radioiodine

• Type: Article in International Scientific Journal
• Date: 2023

Authors

Fernandes, A (Author) Other; Oliveira, A (Author) Other; Carvalho, AL (Author) Other; soares, r (Author) FMUP; Barata, P (Author) Other

Journal

Title: Nutrients

Vol. 15 No. 4

Final page: 2680

ISSN: 2072-6643

Publisher: MDPI

Indexing

ISI Web of Knowledge - 4 Citations

Scopus - 4 Citations

Other information

Authenticus ID: P-00Y-KW1

DOI: 10.3390/nu15122680

Abstract (EN): Background: Faecalibacterium prausnitzii, one of the most important bacteria of the human gut microbiota, produces butyrate (a short-chain fatty acid). Short-chain fatty acids are known to influence thyroid physiology and thyroid cancer's response to treatment. We aimed to analyze the relative abundance of Faecalibacterium prausnitzii on the gut microbiota of differentiated thyroid cancer patients compared to controls and its variation after radioiodine therapy (RAIT). Methods: Fecal samples were collected from 37 patients diagnosed with differentiated thyroid cancer before and after radioiodine therapy and from 10 volunteers. The abundance of F. prausnitzii was determined using shotgun metagenomics. Results: Our study found that the relative abundance of F. prausnitzii is significantly reduced in thyroid cancer patients compared to volunteers. We also found that there was a mixed response to RAIT, with an increase in the relative and absolute abundances of this bacterium in most patients. Conclusions: Our study confirms that thyroid cancer patients present a dysbiotic gut microbiota, with a reduction in F. prausnitzii's relative abundance. In our study, radioiodine did not negatively affect F. prausnitzii, quite the opposite, suggesting that this bacterium might play a role in resolving radiation aggression issues.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 14